AXSMAxsome Therapeutics, Inc.
Is it safe?
Forensics clean, with a caveat: a safe balance sheet, but heavy debt (BB).
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Insiders were net sellers (-$12.6M, 90 days to Oct 8, 2026), selling is often routine.
Net cash, but unprofitable, speculative. A rule of thumb on leverage, not a credit rating.
Moderate price swings, typical volatility. Worst drawdown -81% · now 34% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can AXSM take a bad year?
Axsome Therapeutics, Inc. holds $132M more cash than debt, and is burning $18M a quarter, about 4.5 years of cover.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 10.03
Altman Z-score · safe zone, above 3
- Cash runway
- 4.5 years
Cash runway · burning $18M a quarter at the current rate
Details›
- Total debtQ2 2026
- $188M
- Cash and short-term investments
- $320M
- Net cash
- $132M
- EBITDA, trailing twelve months
- −$183M
- Operating profit, trailing twelve months
- −$186M
- Debt / equity
- 2.26×
- Annualised volatilitytwo years of daily moves
- 45%
- Worst drawdown on file
- −81%
- Below its 52-week high
- 34%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.